Women’s Day: LifeCell India launches comprehensive breast screen panel for cancer detection

The revolutionary genetic test helps screen common genes associated with hereditary breast and ovarian cancer in women above 18 years of age

0
90
Above image is for the representational purpose only.
New Delhi: LifeCell, one of India’s leading comprehensive healthcare solutions providers announced the launch of Breast Screen Panel, a comprehensive genetic screening test that assesses the risk of breast cancer in women. This announcement comes in the midst of International Women’s Day which is also aimed at educating women on the importance of preventive healthcare.
A steady increase in breast cancer cases in India poses a major health challenge and it is predicted that 1 in 29 women will develop this cancer during their lifetime. Hence, early detection is the key to saving lives. With traditional screening tests, there still remain limitations related to false-positive results, overdiagnosis, as well as anxiety and discomfort during the procedure. Complementary genetic testing can help in accurately assessing the risk of hereditary breast and ovarian cancers, give patients a sense of certainty and relief regarding their future risk, as well as improve the chances of getting the timely and right treatment.
Commenting on this launch, Ishaan Khanna, CEO & Executive Director, LifeCell International said, “At LifeCell, we believe that every woman deserves equal access to the affordable and best healthcare services. The launch of the Breast Screen panel is no different in fulfilling that commitment. This powerful tool will help women know their risk of developing breast cancer and provide insights to help them and their doctors choose the best option to manage that risk.  We are hopeful that this panel will help close the gaps in the care of women at high risk and help save lives.”
LifeCell’s Breast Screen panel not only screens for the mutations in the most common BRCA1 and BRCA2 genes but also screens for all 20 high and moderate risk non-BRCA genes associated with hereditary breast and ovarian cancer as outlined by the National Comprehensive Cancer Network® (NCCN) guidelines. Additionally, the panel utilizes next-generation sequencing which not only offers higher throughput, coverage (including deletion & duplication), and speed but also higher accuracy than other predictive tests. LifeCell will also offer expert genetic counselling support and verified reports from clinical geneticists to help women navigate through their screening journey.
With the launch of the affordable Breast Screen Panel, women, as well as physicians, will have access to this powerful risk assessment tool to get vital insights that can help save lives.